PHARMACIE DU CENTRE DE VINEUIL : revenue, balance sheet and financial ratios

PHARMACIE DU CENTRE DE VINEUIL is a French company founded 20 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in VINEUIL (41350), this company of category PME shows in 2019 a revenue of 2.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DU CENTRE DE VINEUIL (SIREN 482991981)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C 2 118 190 € 1 932 573 € 2 186 843 € 1 720 070 €
Net income 181 813 € 168 399 € 264 230 € 206 447 € 148 402 € 160 421 € 108 232 € 87 379 € 43 863 €
EBITDA N/C N/C N/C N/C N/C 216 064 € 143 716 € 144 941 € 78 932 €
Net margin N/C N/C N/C N/C N/C 7.6% 5.6% 4.0% 2.6%

Revenue and income statement

In 2024, PHARMACIE DU CENTRE DE VINEUIL generates positive net income of 182 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 44 k€ -> 182 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

181 813 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 35%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 55%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

34.592%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

54.623%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

10.8%

Solvency indicators evolution
PHARMACIE DU CENTRE DE VINEUIL

Sector positioning

Debt ratio
34.59 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good +11 pts over 3 years

In 2024, the debt ratio of PHARMACIE DU CENTRE DE VI... (34.59) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
54.62% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good -19 pts over 3 years

In 2024, the financial autonomy of PHARMACIE DU CENTRE DE VI... (54.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 124.18. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

124.183

Liquidity indicators evolution
PHARMACIE DU CENTRE DE VINEUIL

Sector positioning

Liquidity ratio
124.18 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Watch -14 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE DU CENTRE DE VI... (124.18) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DU CENTRE DE VINEUIL

Positioning of PHARMACIE DU CENTRE DE VINEUIL in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE DU CENTRE DE VINEUIL is estimated at 2 538 243 € (range 1 767 592€ - 3 797 358€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1767k€ 2538k€ 3797k€
2 538 243 € Range: 1 767 592€ - 3 797 358€
NAF 5 année 2024

Valuation method used

Net Income Multiple
181 813 € × 14.0x = 2 538 244 €
Range: 1 767 593€ - 3 797 358€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DU CENTRE DE VINEUIL with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DU CENTRE DE VINEUIL

What is the revenue of PHARMACIE DU CENTRE DE VINEUIL ?

The revenue of PHARMACIE DU CENTRE DE VINEUIL in 2019 is 2.1 M€.

Is PHARMACIE DU CENTRE DE VINEUIL profitable?

Yes, PHARMACIE DU CENTRE DE VINEUIL generated a net profit of 182 k€ in 2024.

Where is the headquarters of PHARMACIE DU CENTRE DE VINEUIL ?

The headquarters of PHARMACIE DU CENTRE DE VINEUIL is located in VINEUIL (41350), in the department Loir-et-Cher.

Where to find the tax return of PHARMACIE DU CENTRE DE VINEUIL ?

The tax return of PHARMACIE DU CENTRE DE VINEUIL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DU CENTRE DE VINEUIL operate?

PHARMACIE DU CENTRE DE VINEUIL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.